Mobia Medical (NASDAQ:MOBI) Price Target Raised to $17.00

Mobia Medical (NASDAQ:MOBI) had its target price upped by JPMorgan Chase & Co. from $15.00 to $17.00 in a report issued on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 35.24% from the stock’s previous close.

MOBI has been the subject of a number of other research reports. Bank of America began coverage on Mobia Medical in a research note on Tuesday, June 2nd. They issued a “buy” rating and a $16.00 target price for the company. Wolfe Research started coverage on Mobia Medical in a report on Tuesday, June 2nd. They issued an “outperform” rating on the stock. The Goldman Sachs Group assumed coverage on Mobia Medical in a research note on Tuesday, June 2nd. They issued a “buy” rating and a $31.00 price objective for the company. Zacks Research upgraded Mobia Medical to a “hold” rating in a research report on Wednesday, June 3rd. Finally, Wall Street Zen upgraded shares of Mobia Medical from a “sell” rating to a “hold” rating in a report on Sunday, June 14th. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $20.75.

Mobia Medical Stock Performance

Shares of NASDAQ MOBI traded down $0.01 during trading hours on Wednesday, hitting $12.57. 29,325 shares of the stock were exchanged, compared to its average volume of 145,131. Mobia Medical has a 12 month low of $10.19 and a 12 month high of $15.29. The firm’s fifty day simple moving average is $12.54. The firm has a market capitalization of $417.94 million and a P/E ratio of -0.65.

Mobia Medical (NASDAQ:MOBI) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($1.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.27). The firm had revenue of $13.51 million during the quarter. Mobia Medical’s revenue for the quarter was up 102.4% compared to the same quarter last year. Research analysts predict that Mobia Medical will post -2.5 EPS for the current year.

Insider Buying and Selling

In related news, CFO Nelson Bunker Curnes bought 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 9th. The shares were purchased at an average cost of $12.79 per share, with a total value of $63,950.00. Following the completion of the acquisition, the chief financial officer directly owned 366,997 shares in the company, valued at approximately $4,693,891.63. The trade was a 1.38% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Mobia Medical News Roundup

Here are the key news stories impacting Mobia Medical this week:

• Positive Sentiment: BTIG Research reaffirmed its Buy rating and set a $19.00 price target, implying substantial upside from the recent trading level. The endorsement reflects confidence in Mobia Medical’s growth prospects. Benzinga analyst rating report
• Positive Sentiment: Second-quarter revenue rose 102.4% year over year to $13.51 million, while gross margin reached 83.2%. Management also forecast 2026 revenue of $54 million to $56 million, above the approximately $53.5 million analyst consensus, representing expected growth of roughly 69% to 75%. Mobia Medical second-quarter 2026 financial results
• Positive Sentiment: Mobia Medical highlighted two-year VNS-REHAB follow-up data showing durable improvements in upper-limb motor function, daily living activities and quality of life. The company also completed its IPO, raising approximately $134 million in net proceeds, strengthening its funding position. Clinical data and IPO highlights
• Neutral Sentiment: The IPO proceeds and continued commercialization could support expansion, but investors will likely focus on how quickly the company converts revenue growth into profitability.
• Negative Sentiment: Mobia Medical reported a second-quarter loss of $1.10 per share, wider than the analyst consensus loss of $0.83 per share. The company remains unprofitable, with analysts expecting a full-year loss of approximately $2.50 per share, creating pressure despite strong sales growth. Mobia Medical earnings report

Mobia Medical Company Profile

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.